Regenerative medicine in the Australian company, Mesoblast Limited (ASX : MSB) (PINK : MBLTY), today announced the highly successful preclinical trial of its adult stem cells in treating degenerative diseases of the intervertebral disks, the primary cause of back pain.

Single injection of low doses of allogeneic or "off-the shelf adult" stem cells Mesoblast’s a badly damaged intervertebral discs resulted in a dramatic change in degenerative process, "" Restoring a disk cartilage, as well as sustained normalization of disc pathology, anatomy and function. Results of a placebo-controlled, randomized study of cells for treating degenerative disc disease Mesoblast in 36 sheep will be presented and highlighted at the World Congress on Osteoarthritis, Osteoarthritis Research Society International (OARSI), which takes place in Montreal, Canada September 10-12.

Six months after a single direct injection in discal cell Mesoblast’s, discs, which were initially severely damaged and degenerated, it was established that they become indistinguishable from healthy non-degenerate discs in histopathology, cartilage content, height and structure. In contrast to the highly degenerated discs, which served as controls and were either not injected or injected with hyaluronic acid, continues to demonstrate a significant reduction in disc height (p <0,01), the disordered structure of the disc (p <0,01), violated histopathology (p <0.01)> tramadol tramadol cod next day buy tramadol